poisar

Stocks · News reference

Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review

Benzinga Newsdesk

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsThe BLA is supported by the results from the successful Phase 3 VITESSE trial –

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DBVT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Dbv Technologies

    DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.

    DBV Technologies announced the submission of a Biologics License Application (BLA) to the FDA for its VIASKIN® Peanut patch, designed to treat peanut allergies in children aged 4-7 years. The application is based on positive results from the Phase 3 VITESSE clinical trial, the largest immunotherapy study conducted in this patient population, involving 654 children. DBV has requested priority review of the BLA.

    DBVT
  2. Dbv Technologies

    DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

    DBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.

    DBVT